Drug Profile
Siplizumab - ITBMed Biopharmaceuticals
Alternative Names: MEDI-507; TCD 601Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Catholic University of Louvain; Ossium Health
- Developer BioTransplant (CEASED); ITBMed Biopharmaceuticals; Massachusetts General Hospital; MedImmune; Ossium Health
- Class Antineoplastics; Antipsoriatics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Urologics
- Mechanism of Action Antibody-dependent cell cytotoxicity; Regulatory T-lymphocyte stimulants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Liver transplant rejection; Renal transplant rejection; Type 1 diabetes mellitus
- Phase I/II Graft-versus-host disease; Transplant rejection
- Discontinued Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; T-cell lymphoma
Most Recent Events
- 25 Mar 2024 ITB-Med in collaboration with University of Alabama plans a phase-0 trial for Hidradenitis suppurativa in January 2025 (SC) (NCT06326476)
- 09 Jan 2024 Phase-II clinical trials in Renal transplant rejection (Combination therapy, Prevention) in USA (IV) (NCT05669001)
- 01 Oct 2023 Phase-I/II clinical trials in Renal transplant rejection in USA (IV) (NCT05900401)